Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Bentall, Richard P.
and
Day, Jennifer C.
1994.
Psychological factors and neuroleptic therapy: Some neglected issues.
International Review of Psychiatry,
Vol. 6,
Issue. 2-3,
p.
217.
McIntyre, Carmen
and
Simpson, George M
1995.
How Much Neuroleptic is Enough?.
Psychiatric Annals,
Vol. 25,
Issue. 3,
p.
135.
Lader, M
1995.
Treatment models.
European Psychiatry,
Vol. 10,
Issue. S1,
p.
33s.
Peterson, G. M.
McLean, S.
Westhead, T. T.
and
Gillies, P.
1995.
Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
Journal of Clinical Pharmacy and Therapeutics,
Vol. 20,
Issue. 2,
p.
55.
Carvajal, Alfonso
and
Martín Arias, Luis H.
1995.
Vol. 19,
Issue. ,
p.
40.
Barbui, C
and
Saraceno, B
1996.
Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: An effect size analysis.
European Psychiatry,
Vol. 11,
Issue. 8,
p.
412.
Kuperberg, GR
and
Murray, R
1996.
ADVANCES IN THE TREATMENT OF SCHIZOPHRENIA.
International Journal of Clinical Practice,
Vol. 50,
Issue. 6,
p.
315.
Oliveira, I. R.
Sena, E. P.
Pereira, E. L. A.
Miranda, A. M. A.
Oliveira, N. F.
Ribeiro, M. G.
Castro-e-Silva, E.
Dardennes, R. M.
Samuel-Lajeunesse, B.
and
Marcilio, C.
1996.
Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis.
Journal of Clinical Pharmacy and Therapeutics,
Vol. 21,
Issue. 4,
p.
229.
Day, J. C.
Bentall, R. P.
and
Warnel, S.
1996.
Schizophrenic patients' experiences of neuroleptic medication: a Q‐methodological investigation.
Acta Psychiatrica Scandinavica,
Vol. 93,
Issue. 5,
p.
397.
Lindström, Leif H.
and
Wieselgren, Ing-Marie
1996.
Schizophrenia and Antipsychotic Somatic Treatment.
International Journal of Technology Assessment in Health Care,
Vol. 12,
Issue. 4,
p.
573.
Ungvari, G. S.
Pang, A. H. T.
Chiu, H. F. K.
Wong, C. K.
and
Lum, F. C. K.
1996.
Psychotropic drug prescription in rehabilitation.
Social Psychiatry and Psychiatric Epidemiology,
Vol. 31,
Issue. 5,
p.
288.
Barbui, C
Saraceno, B
Liberati, A
and
Garattini, S
1996.
Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials.
European Psychiatry,
Vol. 11,
Issue. 6,
p.
306.
Troisi, Alfonso
Pasini, Augusto
De Angelis, Francesca
and
Spalletta, Gianfranco
1997.
Paranoid/Belligerence and Neuroleptic Dosage in Newly Admitted Schizophrenic Patients.
Journal of Clinical Psychopharmacology,
Vol. 17,
Issue. 2,
p.
84.
Barbui, C.
and
Saraceno, B.
1997.
Terapia neuroléptica a dosis bajas y efectos secundarios extrapiramidales en esquizofrenia: un análisis del tamaño del efecto.
European psychiatry (Ed. Española),
Vol. 4,
Issue. 5,
p.
323.
Miller, Robert
1997.
Dose-response relationships for the antipsychotic effects and Parkinsonian side-effects of typical neuroleptic drugs: Practical and theoretical implications.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 21,
Issue. 7,
p.
1059.
van den Burg, Willem
1998.
De (in)effectiviteit van psychofarmaca.
Dth,
Vol. 18,
Issue. 1,
p.
1.
Remington, Gary
Kapur, Shitij
and
Zipursky, Robert B.
1998.
Pharmacotherapy of first-episode schizophrenia.
British Journal of Psychiatry,
Vol. 172,
Issue. S33,
p.
66.
Haberfellner, E.M.
and
Rittmannsberger, H.
1999.
Discrepancy between objective weight gain and recognition as a side effect of anti-psychotic treatment.
European Psychiatry,
Vol. 14,
Issue. 5,
p.
298.
Carpenter, Jr., William T.
Buchanan, Robert W.
Kirkpatrick, Brian
Lann, Helen D.
Breier, Alan F.
and
Summerfelt, Ann T.
1999.
Comparative Effectiveness of Fluphenazine Decanoate Injections Every 2 Weeks Versus Every 6 Weeks.
American Journal of Psychiatry,
Vol. 156,
Issue. 3,
p.
412.
Kapur, Shitij
Zipursky, Robert B.
and
Remington, Gary
1999.
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia.
American Journal of Psychiatry,
Vol. 156,
Issue. 2,
p.
286.